Trial Profile

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mobocertinib (Primary) ; Carboplatin; Pemetrexed
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Proof of concept; Registrational; Therapeutic Use
Acronyms EXCLAIM
Sponsors Takeda; Takeda Oncology

Most Recent Events

06 Mar 2025 Planned End Date changed from 28 Mar 2025 to 31 Oct 2026.
06 Mar 2025 Planned primary completion date changed from 28 Mar 2025 to 31 Oct 2026.
17 Oct 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com